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Abstract.13
Background: Alzheimer’s disease (AD) has been associated with dysregulation of brain cholesterol trafficking and abnormal
production of apolipoprotein E isoform 4 (apoE4). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein present
in serum and cerebrospinal fluid (CSF) degrading the low-density lipoprotein receptor (LDLr) and other apoE-binding
receptors involved in neuron cholesterol uptake. The role of PCSK9 in AD is controversial.
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Objective: We compared PCSK9 levels in CSF of AD patients and non-AD controls and looked at correlations with CSF
total apoE and apoE4.
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Methods: CSF from AD (n = 30) and from age and sex-matched non-AD patients (n = 30) was collected by lumbar puncture
for routine diagnosis. CSF PCSK9, total apoE, and apoE4 levels were measured by ELISA. AD patients showed the typical
CSF neurobiomarker pattern (decreased A42 and increased tau and phospho-tau) and impaired cognitive performances, as
indicated by the scores of the Mini-Mental State Examination test.
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Results: PCSK9 levels in CSF were higher in AD than in non-AD subjects (+1.45 fold; p = 0.0049). CSF total apoE con-
centrations did not differ between the two groups, while apoE4 levels were higher in AD subjects (+3.34 fold; p = 0.0068).
Considering all samples, a significant positive correlation was found between PCSK9 and apoE4 (r = 0.4409; p = 0.0006).
PCSK9 levels were higher in APOE ε4 carriers, reaching statistical significance in the AD group (+1.45 fold; p = 0.0454).
24
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Conclusion: These results report for the first time an alteration of CSF PCSK9 levels in AD and suggest a pathophysiological
link between PCSK9, apoE4, and AD.
28
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INTRODUCTION32
Alterations of cholesterol homeostasis in the cen-33
tral nervous system (CNS) have been associated34
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with various neurodegenerative disorders, including 35
Alzheimer’s disease (AD). 36
The relationship between lipid homeostasis 37
derangement and AD, in particular, is suggested by 38
growing evidence. For example, dyslipidemia, a com- 39
mon condition leading to cardiovascular diseases, 40
is also a risk factor for AD onset [1]; in addition, 41
genomic-wide association studies have identified 42
several loci involved in lipid metabolism among AD
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susceptible genes [2]. Apolipoprotein E4 (apoE4),43
a molecule that strongly associates with a higher44
AD risk, has a reduced capacity to be lipidated45
and to modulate cell cholesterol trafficking com-46
pared to other apoE isoforms, both at periphery and47
in CNS [3, 4]. Cell cholesterol metabolism at cen-48
tral level involves the production of apoE-containing49
high-density lipoprotein (HDL)-like particles that are50
transported in cerebrospinal fluid (CSF) and that51
redistribute cholesterol to neurons. This function52
ensures synaptogenesis and physiological functions53
maintenance. Disturbances of such cholesterol flux54
may play an important role in neurodegenerative dis-55
orders [5].56
Proprotein convertase subtilisin/kexin type 957
(PCSK9) is a serine protease firstly described to tar-58
get hepatic low-density lipoprotein receptor (LDLr)59
and to mediate its degradation [6]. Gain-of-function60
PCSK9 mutations lead to increased levels of serum61
LDL cholesterol and loss-of-function mutations pre-62
vent the degradation of the hepatic LDL, resulting63
in a higher clearance of plasma LDL-cholesterol [7].64
However, PCSK9 has several extrahepatic effects [8].65
PCSK9 was firstly identified in the brain [9] and is66
detectable in the CSF of healthy subjects without the67
typical diurnal pattern of plasma PCSK9, indicating68
a different regulation in the two body compartments69
[10]. In neurons, PCSK9 has been shown to degrade70
LDLr as well as other apoE-binding receptors such as71
the very low-density lipoprotein receptor (VLDLr),72
the LDL receptor–related protein 1 (LRP1) and the73
apolipoprotein E receptor 2 (apoER2) [11, 12]; these74
proteins are involved in the internalization of the75
cholesterol transported within CSF by HDL-like par-76
ticles [5, 12]. Thus, PCSK9 modified activity might77
in principle be involved in the derangement of brain78
cholesterol trafficking and lipoprotein homeostasis79
and in AD pathogenesis. In this work, we measured80
PCSK9 in CSF of AD patients to establish whether81
PCSK9 levels alterations occur in AD and looked for82
a correlation between PCSK9 values and CSF total83
apoE and apoE4.84
MATERIALS AND METHODS85
Subjects and methods86
CSF samples from AD patients (n = 30) and age-87
and sex-matched non-AD controls (n = 30) were col-88
lected at the Neurology Units of Parma and Milano89
after written informed consent obtained using a form90
approved by the local Ethics Committee. The study91
was performed in accordance with the ethical princi- 92
ples set in the Declaration of Helsinki of 1975. CSF 93
was collected between 8 and 10 a.m. after one night 94
fasting by lumbar puncture for routine clinical diag- 95
nosis and immediately stored at –80◦C. None of the 96
samples presented alterations at the physicochemical 97
evaluation. 98
The diagnosis of AD was made according to 99
NINCDS-ADRDA [13] and subsequent research 100
criteria [14]. The CSF neurobiomarker profile 101
(amyloid- (A)42, tau, and phospho-tau levels) was 102
evaluated by ELISA (Fujirebio, Ghent, Belgium). 103
Global cognitive performance was assessed with the 104
Mini-Mental State Examination (MMSE) test. All 105
clinical diagnoses of non-AD control subjects were 106
reported in Table 1. This group included subjects 107
that experienced cognitive symptoms (n = 6) [psy- 108
chiatric disorders (n = 4), alcohol abuse (n = 1), and 109
dural fistula (n = 1)], but in which clinical examina- 110
tion revealed disorders not related to AD, as indicated 111
by the values of the neurochemical markers reported 112
in Table 2. The other non-AD diagnoses (n = 24) 113
include neurological disorders, hydrocephalus, not 114
confirmed CNS diseases, and neuropathies (Table 1). 115
Table 1
Clinical diagnosis of non-AD control subjects
Clinical diagnosis Number of subjects
(total N = 30)
Psychiatric disorders 9
Neurological disorders 7
Hydrocephalus 4
Not confirmed CNS disease 4
Alcohol abuse 1
Dural fistula 1
Hypoacusis 1
Other tumors 1
Graves-Basedow disease 1
Stroke 1
Table 2
Demographic data and AD diagnostic parameters
Variable Non-AD (N = 30) AD (N = 30) p-value
Demographics
Age (years) 60 ± 20 68 ± 8 NS
Male sex, n (%) 13 (43%) 12 (40%) NS
Diagnostic parameters N = 6∗ N = 30
A1−42 (ng/L) 1163 ± 414 537 ± 148 0.0002
Tau (ng/L) 138 ± 40 640 ± 461 <0.0001
Phospho-tau (ng/L) 32 ± 7 78 ± 29 <0.0001
MMSE (points) – 21.43 ± 4.14 NA
MMSE, Mini-Mental State Examination; NS, not significant; NA,
not applicable. Data are expressed as Mean ± S.D. Nonparamet-
ric two-sided Mann-Whitney test was applied to compare the two
groups. ∗Non-AD subjects that experienced cognitive symptoms.
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AD patients showed the typical neurobiomarker116
pattern, with decreased concentration of CSF A42,117
reflecting retention of the peptide in the brain118
parenchyma, and increased concentration of tau and119
phospho-tau protein, related to neurodegeneration120
(Table 2). In addition, all AD patients displayed121
MMSE score below 23 points. CSF PCSK9 levels122
and total apoE and apoE4 were measured by ELISA123
(R&D Systems, Minneapolis, MN, USA and MBL,124
Nagoya, Japan, respectively). CSF total apoE and125
apoE4 levels measurement was performed on 27 out126
of 30 AD patients, because 3 patients’ aliquots were127
insufficient for all assays.128
Statistical analysis129
The sample size was calculated a priori by using130
The G*Power software [selecting t-test, difference131
between two independent means (two groups) and132
a priori power analysis]. Statistical analysis was133
performed with Graph Pad-Prism software version134
5.0. Depending on variances analysis results, the135
two-tailed unpaired Student’s t-test (for not statisti-136
cally different variances) or two-sided nonparametric137
Mann-Whitney test (for statistically different vari-138
ances) was applied to compare non-AD and AD139
patients’ values. Relationships between parameters140
were performed by nonparametric correlation (Spear-141
man r reported). Significant differences were defined142
as p < 0.05.143
RESULTS144
The analysis of CSF revealed that PCSK9 levels145
were significantly higher in AD patients than in non-146
AD controls (+1.45 fold; p = 0.0049, Fig. 1A). In147
addition, CSF total apoE concentrations did not differ148
between the two groups (Fig. 1B); conversely, levels149
of the isoform apoE4 were higher in CSF of AD sub-150
jects compared to non-AD (+3.34 fold; p = 0.0068,151
Fig. 1C).152
We found a positive correlation between CSF total153
apoE and A42 levels in the AD group (r = 0.4007;154
p = 0.025), as previously seen by others [15]. With155
respect to the relationship between PCSK9 and apoE156
in CSF, considering all samples together, PCSK9 did157
not significantly correlate with total apoE (p = 0.3656,158
data not shown), but it positively correlated with159
apoE4 levels (Fig. 2A). Since apoE4 production is160
discrete and not continuous according to the null,161
heterozygous or homozygous genotype, the ratio162
apoE4/total apoE can be used to identify APOE ε4163
genotype [16]. Based on this concept we defined as 164
APOE ε4 carriers the individuals with apoE4/apoE 165
ratio >0 (n = 26). Interestingly we found that CSF 166
PCSK9 levels were slightly and almost significantly 167
higher in APOE ε4 carriers among the non-AD 168
subjects (+1.83 fold; p = 0.0775; Fig. 2B); this differ- 169
ence reached statistical significance in the AD group 170
(+1.45 fold; p = 0.0454; Fig. 2C). 171
DISCUSSION 172
Although relative to a small sample size, our results 173
show, for the first time, an increase of PCSK9 levels 174
in CSF of AD patients. A potential involvement of 175
PCSK9 in neurodegenerative conditions such as AD 176
has been already suggested, but the existing reports 177
are few and controversial. 178
For instance, a pro-apoptotic effect of PCSK9 in 179
neurons has been proposed [17]. It was also recently 180
shown that PCSK9 levels are elevated in serum of 181
both mild cognitive impairment and AD patients 182
[18]. Conversely, others reported a protective role 183
of PCSK9 with respect to AD development, based 184
on its degrading action on the -site of amyloid- 185
protein precursor (APP) cleaving enzyme (BACE- 186
1), involved in A42 production [19]. However, the 187
latter effect was denied by the results of Liu and col- 188
leagues [20]. Finally, results of genetic studies did 189
not find any association between PCSK9 polymor- 190
phism and risk of AD onset [21, 22]. Our finding 191
of increased CSF levels of PCSK9 in AD patients 192
supports its involvement in AD pathogenesis. 193
It is hard at present to establish whether the 194
increase of PCSK9 in the CSF is a consequence of 195
AD or a causative factor. In this regard, it is relevant 196
to consider that the PCSK9 expression in neuronal 197
cells is stimulated in response to injury, as upon 198
induction of apoptosis. In any case, an increased 199
PCSK9 production is likely to be a pathogenic fac- 200
tor. First of all, high CSF PCSK9 levels might be 201
associated to a reduced neuronal expression of the 202
apoE-receptors in AD. This hypothesis is supported 203
by the reported action of PCSK9 on neuronal apoE 204
receptors such as LDLr, VLDLr, LRP1, and apoER2, 205
implicated in brain lipid metabolism and AD patho- 206
genesis [12]; consistently with this hypothesis, it 207
has been recently shown that the plant-derived com- 208
pound berberine is able to decrease PCSK9 neuronal 209
expression and to upregulate the VLDLr and LRP 210
[23]. Finally, an increased expression of the LDLr 211
has been observed in brain of PCSK9–/– mice [24]. 212
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Fig. 1. PCSK9 (A), total apoE (B), and apoE4 (C) levels in CSF from non-AD (n = 30) and AD (n = 30) patients. Each sample was run in
duplicate. A, B) Two-tailed unpaired t-test was applied to compare the two groups. C) Nonparametric two-sided Mann-Whitney test was
applied to compare the two groups. Mean ± SEM is reported.
Fig. 2. Relationship between PCSK9 and apoE4 levels in CSF from non-AD and AD patients. A) Correlation between CSF PCSK9 and
apoE4 levels in pooled non-AD and AD samples (n = 57). Analysis was performed by nonparametric correlation and Spearman r is reported.
B) PCSK9 levels in non-carriers (n = 21) and carriers (n = 9) of APOE ε4 among non-AD subjects. C) PCSK9 levels in non-carriers (n = 10)
and carriers (n = 17) of APOE ε4 among AD patients. Each sample was run in duplicate. Nonparametric two-sided Mann-Whitney test was
applied in the case of non-AD subjects and two-tailed unpaired Student’s t-test was used for AD patients. Mean ± SEM is reported.
Reduced apoE receptor expression might in turn213
cause less cholesterol uptake, and possibly neuronal214
dysfunctions. In facts, while cholesterol synthesis in215
neurons and glial cells is high during embryogen-216
esis, adult neurons progressively lose this capacity217
and almost exclusively rely on cholesterol produced218
from astrocytes to maintain neuronal development219
and synaptic plasticity [5]. In addition, beyond its220
potential involvement in altered apoE-mediated lipid221
trafficking, high PCSK9 levels might affect A222
deposition, one of the key events in AD pathogen-223
esis. Indeed, the brain endothelial LRP1, which is224
degraded by PCSK9 [11], was recently shown to be225
involved in the A clearance from the CSF. LRP1226
deletion results in reduced plasma A, elevated brain227
A deposition, and cognitive impairment in AD ani-228
mal models [25].229
Total apoE levels in CSF from our AD patients did230
not differ from those of controls, consistently with the231
results of a recent meta-analysis [26]. It may be spec-232
ulated that, although increased apoE levels would233
be expected because of PSCK9-mediated receptor234
degradation, the apoE binding to A causes retention235
of apoE within the plaques, not allowing appreciat-236
ing significant differences. The positive association237
between apoE levels and A42 seen in our present 238
work and in others’ [15] would be consistent with 239
this hypothesis. 240
Conversely, apoE4 levels were significantly higher 241
in the AD group, in accordance with the increased 242
occurrence of apoE ε4 genotype in this disease [27]. 243
Interestingly, analyzing all CSF samples, we found a 244
positive correlation between PCSK9 and apoE4 lev- 245
els, clearly indicating a relationship between these 246
two lipid-regulating molecules in the CNS. Such cor- 247
relation was better clarified comparing CSF PCSK9 248
in APOE ε4 genotype carriers and non-carriers in 249
both AD and non-AD subjects. Indeed, PCSK9 levels 250
were higher in APOE ε4 carriers compared to non- 251
carriers, reaching statistical significance in the AD 252
group. The mechanisms of the relationship between 253
PCSK9 and apoE4 levels need to be explored, but 254
a role of apoE4 in modulating PCSK9 production 255
might be speculated; this hypothesis may be in line 256
with the recently proposed role of apoE4 as transcrip- 257
tional factor [28]. 258
The limitations of this study are the small sample 259
size and the characteristics of non-AD controls, the 260
majority of which are patients with neurological or 261
psychiatric diseases. This is because CSF collection 262
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is an invasive procedure, only practicable in the pres-263
ence of strict clinical indication.264
However, given the variety of conditions included265
in our study and because of the lack of a relationship266
between PCSK9 values and diagnosis in the control267
group, it is very unlikely that the significant differ-268
ence in CSF PCSK9 levels between AD and non-AD269
patients may be affected by control group composi-270
tion.271
In conclusion, to the best of our knowledge, the272
results of this study suggest for the first time a273
possible link between PCSK9 levels, apoE4, and274
AD. Further studies are needed to fully elucidate275
the mechanisms relating PCSK9 modifications, brain276
cholesterol homeostasis, and AD development.277
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